Maralixibat: all 23 studies that test it
Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)Not yet recruitingNCT07823127Phase 2
- Maralixibat for Intrahepatic Cholestasis of PregnancyNot yet recruitingNCT07389031Phase 2
- Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)RecruitingNCT07290257Phase 4
- Maralixibat in Patients With Cystic Fibrosis and ConstipationRecruitingNCT06413368Phase 2/3
- A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedNCT05543187Phase 3Results posted
- A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)CompletedNCT05543174Phase 3Results posted
- A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).CompletedNCT04729751Phase 2Results posted
- Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiCompletedNCT04524390Phase 2Results posted
- An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedNCT04185363Phase 3Results posted
- MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyCompletedNCT04168385Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)CompletedNCT03905330Phase 3Results posted
- Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)CompletedNCT02160782Phase 2Results posted
- An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille SyndromeCompletedNCT02117713Phase 2Results posted
- Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing CholangitisCompletedNCT02061540Phase 2Results posted
- Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic CholestasisCompletedNCT02057718Phase 2Results posted
- Evaluation of LUM001 in the Reduction of Pruritus in Alagille SyndromeCompletedNCT02057692Phase 2Results posted
- An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)CompletedNCT02047318Phase 2Results posted
- Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary CirrhosisCompletedNCT01904058Phase 2Results posted
- Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille SyndromeCompletedNCT01903460Phase 2Results posted
- Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Active, not recruitingNCT06553768Phase 3
- A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)WithdrawnNCT03353454Phase 3
- Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid ExcretionCompletedNCT02475317Phase 1
- An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary CirrhosisWithdrawnNCT02321306Phase 2